Starpharma Holdings
Starpharma Holdings Limited, headquartered in Australia, is a pioneering biotechnology company renowned for its innovative work in drug delivery and development. Founded in 1996, Starpharma has made significant strides in the pharmaceutical industry, particularly in the areas of dendrimer-based therapies and antiviral products. The company’s flagship product, VivaGel®, is a unique antiviral and antibacterial gel that has garnered attention for its efficacy in preventing sexually transmitted infections. Starpharma's commitment to research and development has positioned it as a leader in the biotech sector, with a strong focus on enhancing the safety and effectiveness of existing therapies. With a robust pipeline and strategic partnerships, Starpharma continues to expand its market presence, contributing to advancements in healthcare and improving patient outcomes globally.
DitchCarbon Score
How does Starpharma Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Starpharma Holdings's score of 22 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Starpharma Holdings's reported carbon emissions
In 2023, Starpharma Holdings reported total carbon emissions of approximately 42,240,000 kg CO2e, with emissions distributed across various scopes: 17,200 kg CO2e (Scope 1), 384,500 kg CO2e (Scope 2), and 42,240,000 kg CO2e (Scope 3). This marked a significant increase in total emissions compared to 2022, where total emissions were about 929,920 kg CO2e, comprising 25,670 kg CO2e (Scope 1), 416,680 kg CO2e (Scope 2), and 5,251,000 kg CO2e (Scope 3). In 2024, preliminary data indicates a reduction in Scope 1 and Scope 2 emissions, with Scope 1 emissions at approximately 15,040 kg CO2e and Scope 2 emissions at about 357,180 kg CO2e. However, Scope 3 emissions data for 2024 is not available. Starpharma has not disclosed specific reduction targets or initiatives as part of their climate commitments. The absence of documented reduction targets suggests a need for further clarity on their long-term sustainability strategies. Overall, the company operates within a context of increasing scrutiny on carbon emissions, particularly in the pharmaceutical sector, where comprehensive climate action is becoming increasingly essential.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 50,510 | 00,000 | 00,000 | 00,000 |
| Scope 2 | 25,700 | 000,000 | 000,000 | 000,000 |
| Scope 3 | 5,040,000 | 0,000,000 | 00,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Starpharma Holdings is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
